$RYTM

Rhythm Pharmaceuticals (RYTM) secured a $750M loan facility, with $500M committed, led by KKR’s HealthCare Royalty and Blackstone. The company also amended its license agreement with LG Chem for bivamelagon, an investigational MC4R agonist, including additional fixed payments. Rhythm aims to advance the drug's development for rare obesity diseases, potentially creating long-term value for shareholders.

Rhythm Pharmaceuticals (RYTM) reports Q3 earnings, with analysts expecting a loss of $0.71 per share on revenue of $85.4M. The company's IMCIVREE drug launch for acquired hypothalamic obesity is a key focus, with analysts projecting significant long-term sales potential. The stock has a consensus price target of $140.53, implying 52% upside. Investors will watch for updates on international expansion and early data from Japan.

William Blair initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating, citing optimism about its drug Imcivree and potential in acquired hypothalamic obesity (aHO). The analyst expects significant growth in the U.S., Japan, and Europe.

JP Morgan maintained an Overweight rating for Rhythm Pharmaceuticals (RYTM) but lowered its price target from $146 to $145. The company's stock is currently undervalued by 31.8% according to GF Value™, with a GF Score™ of 56. Rhythm Pharmaceuticals focuses on therapies for rare neuroendocrine diseases, with a market cap of $6.08 billion. Analysts and gurus show mixed signals about the company's prospects.

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity, the first approved treatment for this condition in the country. The drug was included in Japan's National Health Insurance list, following MHLW approval in August. Rhythm estimates 5,000-8,000 people in Japan may have this condition.

H.C. Wainwright raised its price target for Rhythm Pharmaceuticals (RYTM) to $130 from $105, maintaining a Buy rating. The stock trades at $90.78, with analysts' targets ranging from $105 to $160. Japan approved IMCIVREE for acquired hypothalamic obesity, supported by Phase 3 trial data. Rhythm reported Q2 2026 earnings, with revenue of $71.26 million, beating estimates. The company is not yet profitable but has 89% gross margins and 54% revenue growth over the last year.

Rhythm Pharmaceuticals (RYTM) announced Health Canada approved IMCIVREE for weight management in patients with acquired hypothalamic obesity, expanding its existing approvals. The drug is now indicated for patients aged four and older. The company expressed gratitude to the Canadian patient and healthcare community.

Health Canada approved Rhythm Pharmaceuticals' Imcivree for weight management in patients aged 4+ with acquired hypothalamic obesity. The approval is based on a Phase 3 trial showing an 18.8% placebo-adjusted BMI reduction. Imcivree is also approved in the U.S., Europe, and the UK for other obesity-related indications.

Rhythm Pharmaceuticals (RYTM) received Health Canada approval for IMCIVREE (setmelanotide) to treat weight management in patients 4 years and older with acquired hypothalamic obesity. The approval follows a Phase 3 trial showing an 18.8% placebo-adjusted BMI reduction. IMCIVREE is the first targeted therapy for this condition in Canada.

Palatin Technologies (PTN), valued at $20M, is developing melanocortin-receptor drugs for rare obesity, following Rhythm Pharmaceuticals (RYTM) and Neurocrine Biosciences' successes in the space. PTN's programs aim to improve efficacy and tolerability, with clinical trials expected to start in late 2026 and 2027. The market's validation of MC4R targets and rare-obesity drugs could significantly impact PTN's valuation.